These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20170371)

  • 1. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression.
    Euler Z; van Gils MJ; Bunnik EM; Phung P; Schweighardt B; Wrin T; Schuitemaker H
    J Infect Dis; 2010 Apr; 201(7):1045-53. PubMed ID: 20170371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression.
    van Gils MJ; Euler Z; Schweighardt B; Wrin T; Schuitemaker H
    AIDS; 2009 Nov; 23(18):2405-14. PubMed ID: 19770692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity.
    Samuelsson A; Broström C; van Dijk N; Sönnerborg A; Chiodi F
    Virology; 1997 Nov; 238(2):180-8. PubMed ID: 9400591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma.
    Furrer H; Barloggio A; Egger M; Garweg JG;
    Ophthalmology; 2003 Feb; 110(2):432-6. PubMed ID: 12578793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificities of broadly neutralizing anti-HIV-1 sera.
    Binley J
    Curr Opin HIV AIDS; 2009 Sep; 4(5):364-72. PubMed ID: 20048699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
    DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
    J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies.
    Rademeyer C; Moore PL; Taylor N; Martin DP; Choge IA; Gray ES; Sheppard HW; Gray C; Morris L; Williamson C;
    Virology; 2007 Nov; 368(1):172-81. PubMed ID: 17632196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein is a marker for human immunodeficiency virus disease progression.
    Lau B; Sharrett AR; Kingsley LA; Post W; Palella FJ; Visscher B; Gange SJ
    Arch Intern Med; 2006 Jan; 166(1):64-70. PubMed ID: 16401812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 IgA specific serum antibodies and disease progression during HIV-1 infection.
    Margalith M; Levy E; Rinaldo CR; Detels R; Phair J; Kaslow R; Saah AJ; Sarov B
    J Hum Virol; 2001; 4(5):269-77. PubMed ID: 11907384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of HIV-1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T-cell count.
    Kupfer B; Kaiser R; Rockstroh JK; Matz B; Schneweis KE
    J Med Virol; 1998 Nov; 56(3):259-63. PubMed ID: 9783695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS.
    Blattner WA; Oursler KA; Cleghorn F; Charurat M; Sill A; Bartholomew C; Jack N; O'Brien T; Edwards J; Tomaras G; Weinhold K; Greenberg M
    J Infect Dis; 2004 May; 189(10):1793-801. PubMed ID: 15122515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects.
    Cecilia D; Kleeberger C; Muñoz A; Giorgi JV; Zolla-Pazner S
    J Infect Dis; 1999 Jun; 179(6):1365-74. PubMed ID: 10228056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V; Diemert MC; Braibant M; Potard V; Charuel JL; Barin F; Costagliola D; Caumes E; Clauvel JP; Autran B; Musset L;
    Clin Infect Dis; 2009 Jan; 48(1):123-32. PubMed ID: 19035778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to an eight-site intradermal rabies vaccination in patients infected with Human Immunodeficiency Virus.
    Sirikwin S; Likanonsakul S; Waradejwinyoo S; Pattamadilok S; Kumperasart S; Chaovavanich A; Manatsathit S; Malerczyk C; Wasi C
    Vaccine; 2009 Jul; 27(32):4350-4. PubMed ID: 19487057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients.
    Veit O; Niedrig M; Chapuis-Taillard C; Cavassini M; Mossdorf E; Schmid P; Bae HG; Litzba N; Staub T; Hatz C; Furrer H;
    Clin Infect Dis; 2009 Mar; 48(5):659-66. PubMed ID: 19191654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral burden and disease progression in rhesus monkeys infected with chimeric simian-human immunodeficiency viruses.
    Reimann KA; Watson A; Dailey PJ; Lin W; Lord CI; Steenbeke TD; Parker RA; Axthelm MK; Karlsson GB
    Virology; 1999 Mar; 256(1):15-21. PubMed ID: 10087222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.